Strata Critical Medical, Inc. (SRTA) Guidance & Earnings Results
On 2026-03-03 Strata Critical Medical, Inc. raised guidance: "FY2026 revenue $260-275M, Adj. EBITDA…" — from its own filing, as read by EquiReason.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
SRTAStrata Critical Medical, Inc.Follow SRTA — free
—
Price chart with a free account
- Market cap
- 412.3M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 9 Nov, in 16 days
What management guided
each earnings 8-K · figures checked against the filing text| Release | Direction | What they said |
|---|---|---|
| 3 Mar 26 | Raised | FY2026 revenue $260-275M, Adj. EBITDA $29-33M · full year |
| 10 Nov 25 | Raised | Revenue guidance raised to $185-195 million from prior range · full year |
| 5 Aug 25 | Reaffirmed | FY2025 revenue $245-265 million; Double-digit Adjusted EBITDA (no specific number given) · full year |
Strata Critical Medical, Inc. — questions
- What guidance did Strata Critical Medical, Inc. give?
- On 2026-03-03: "FY2026 revenue $260-275M, Adj. EBITDA $29-33M"
- When does Strata Critical Medical, Inc. report earnings?
- Strata Critical Medical, Inc.'s next earnings report is expected on 2026-11-09.
Every figure on this page comes from Strata Critical Medical, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.